Hyman, David M.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 3,380

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 2,824

A view on drug resistance in cancer

Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature

Cancer Cells and MetastasisDrug Transport and Resistance Mechanisms

Cited by 2,770

AACR Project GENIE: Powering Precision Medicine through an International Consortium

The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 1,964

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 1,764

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,142

Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 1,028

Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes

Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 866

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M. T. A., et al. (2018) · Cancer Cell

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 858

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 780

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

Bolton, K. L., Ptashkin, R. N., Gao, T., Braunstein, L., Devlin, S. M., Kelly, D., Patel, M., Berthon, A., Syed, A., Yabe, M., et al. (2020) · Nature Genetics

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 751

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 643

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research

Hepatocellular Carcinoma Treatment and PrognosisCancer Genomics and Diagnostics

Cited by 602

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making

Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 541

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy

Cited by 504

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology

Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 476

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., Mandelker, D., Zehir, A., Capanu, M., Salo-Mullen, E., et al. (2018) · JNCI: Journal of the National Cancer Institute

Pancreatic and Hepatic Oncology ResearchBRCA gene mutations in cancer

Cited by 224

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., et al. (2019) · Nature Medicine

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 195

Development of genome-derived tumor type prediction to inform clinical cancer care

Penson, A., Camacho, N., Zheng, Y., Varghese, A. M., Al-Ahmadie, H., Razavi, P., Chandarlapaty, S., Vallejo, C. E., Vakiani, E., Gilewski, T., et al. (2020) · JAMA Oncology

Cancer Genomics and DiagnosticsCancer Diagnosis and Treatment

Cited by 115

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

Schram, A. M., Gandhi, L., Mita, M. M., Damstrup, L., Campana, F., Hidalgo, M., Grande, E., Hyman, D. M., & Heist, R. S. (2018) · British Journal of Cancer

PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK Pathways

Cited by 96

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 94

Toward a More Precise Future for Oncology

Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 48